Enhertu Shows Promise as First-Line Treatment for Metastatic . . . ,व्यापार निर्देशिकाएँ , कंपनी निर्देशिकाएँ

companydirectorylist.com वैश्विक व्यापार निर्देशिकाएँ और कंपनी निर्देशिकाएँ

देश सूचियाँ

संयुक्त राज्य अमेरिका कंपनी निर्देशिकाएँ

कनाडा व्यापार सूचियाँ

ऑस्ट्रेलिया व्यापार निर्देशिका

फ्रांस कंपनी सूची

इटली कंपनी सूचियाँ

स्पेन कंपनी निर्देशिका

स्विटज़रलैंड व्यवसाय सूची

ऑस्ट्रिया कंपनी निर्देशिका

बेल्जियम व्यापार निर्देशिका

हांगकांग कंपनी सूचियाँ

चीन व्यापार सूचियाँ

ताइवान की कंपनी सूचियाँ

संयुक्त अरब अमीरात कंपनी निर्देशिकाएँ

उद्योग कैटलॉग

संयुक्त राज्य अमेरिका उद्योग निर्देशिकाएँ

English Français Deutsch Español 日本語 한국의 繁體简体 Português Italiano Русский हिन्दी ไทย Indonesia Filipino Nederlands Dansk Svenska Norsk Ελληνικά Polska Türkçe العربية

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Patient Website
How will I receive ENHERTU? You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider ENHERTU is given 1 time every three weeks (21-day treatment cycle) Your healthcare provider will decide how many treatments you need
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
Find valuable information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results, safety information, [downloadable resources,] and more
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
Find valuable information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results, safety information, downloadable resources, and more
HER2-positive mBC ENHERTU® (fam-trastuzumab deruxtecan-nxki)
What is ENHERTU? ENHERTU is a prescription medicine used to treat adults who have human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment: for metastatic disease, or
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | About ENHERTU
ENHERTU is given as an intravenous (IV) infusion once every 3 weeks You will receive an ENHERTU infusion either at your oncologist's office or at a nearby infusion center
About ENHERTU | ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2 . . .
Find information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), how it is thought to work, and how it is received See Full Safety, Boxed WARNINGS, and Medication Guide for more information
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Patient Site
Find information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results, safety information, downloadable resources, and more See Full Safety, Boxed WARNINGS, and Medication Guide for more information
ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Potential Side Effects
Find information about potential side effects that may happen with ENHERTU® (fam-trastuzumab deruxtecan-nxki) and tips to help manage these side effects with your doctor